Fig. 2.

In vivo efficacy of PI3K ± MEK inhibition in established intracranial TNBC. (A) Experimental schedule. (B) The median survival (MS) and number of mice alive at the end of the study for mice with intracranial SUM149, MDA-MB-231Br, MDA-MB-468, or MDA-MB-436 tumors. Median survival (MS) for treatment groups statistically different from control (*) or buparlisib (^). Kaplan–Meier curves by treatment group for the (C) SUM149, (D) MDA-MB-231Br, (E) MDA-MB-468, and (F) MDA-MB-436 models. Vertical dotted lines indicate the study’s end.